{"id":16052,"date":"2022-04-01T13:18:22","date_gmt":"2022-04-01T11:18:22","guid":{"rendered":"https:\/\/convergences.online\/hemato\/?p=16052"},"modified":"2022-04-01T13:18:22","modified_gmt":"2022-04-01T11:18:22","slug":"prise-en-charge-du-myelome-multiple-en-rechute-et-multirefractaire-locommotion-1ere-etude-internationale-prospective-observationnelle","status":"publish","type":"post","link":"https:\/\/www.hematostat.net\/en\/prise-en-charge-du-myelome-multiple-en-rechute-et-multirefractaire-locommotion-1ere-etude-internationale-prospective-observationnelle\/","title":{"rendered":"Prise en charge du my\u00e9lome multiple en rechute et multir\u00e9fractaire LocoMMotion : 1\u00e8re \u00e9tude internationale, prospective, observationnelle"},"content":{"rendered":"<p>LocoMMotion : 1\u00e8re \u00e9tude prospective men\u00e9e dans des conditions de vie r\u00e9elle pour \u00e9valuer l\u2019efficacit\u00e9 et la tol\u00e9rance des traitements administr\u00e9s en 4\u00e8me ligne et plus chez 248 patients atteints d\u2019un my\u00e9lome multiple en rechute, r\u00e9fractaire aux trois principales classes th\u00e9rapeutiques disponibles. Plus de 90 protocoles diff\u00e9rents administr\u00e9s \u00e0 ces patients.<\/p>","protected":false},"excerpt":{"rendered":"<p>LocoMMotion : 1\u00e8re \u00e9tude prospective men\u00e9e dans des conditions de vie r\u00e9elle pour \u00e9valuer l\u2019efficacit\u00e9 et la tol\u00e9rance des traitements administr\u00e9s en 4\u00e8me ligne et plus chez 248 patients atteints [&hellip;]<\/p>","protected":false},"author":17,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[21],"tags":[],"ppma_author":[457],"class_list":["post-16052","post","type-post","status-publish","format-standard","hentry","category-communique-de-presse","author-pascale-raoul"],"aioseo_notices":[],"authors":[{"term_id":457,"user_id":17,"is_guest":0,"slug":"pascale-raoul","display_name":"Pascale Raoul","avatar_url":"https:\/\/secure.gravatar.com\/avatar\/?s=96&d=mm&r=g","first_name":"","last_name":"","user_url":"","description":""}],"_links":{"self":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16052","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/users\/17"}],"replies":[{"embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/comments?post=16052"}],"version-history":[{"count":0,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/posts\/16052\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/media?parent=16052"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/categories?post=16052"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/tags?post=16052"},{"taxonomy":"author","embeddable":true,"href":"https:\/\/www.hematostat.net\/en\/wp-json\/wp\/v2\/ppma_author?post=16052"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}